Plasma Proteomic Biomarkers of Aortic Stenosis: A Mendelian Randomization Study
- PMID: 39084832
- DOI: 10.1016/j.jacc.2024.05.046
Plasma Proteomic Biomarkers of Aortic Stenosis: A Mendelian Randomization Study
Conflict of interest statement
Funding Support and Author Disclosures This study has been funded by the Canadian Institutes of Health Research (CIHR), the Heart and Stroke Foundation of Canada (HSFC), the National Institutes of Health, and the U.S. Department of Veterans Affairs. Dr Natarajan has received research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech/Roche, and Novartis; has received personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Eli Lilly & Co, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis; has held scientific advisory board membership for Esperion Therapeutics, Preciseli, and TenSixteen Bio; has served as a scientific cofounder of TenSixteen Bio; has held equity in MyOme, Preciseli, and TenSixteen Bio; and has disclosed spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. Dr Thanassoulis has received consulting fees from Ionis Pharmaceuticals; and has participated in advisory boards for Amgen, Sanofi, Novartis, HLS Therapeutics, and Silence. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources